Immuno Oncology

Immuno Oncology

Cardiovascular Risks Associated With Checkpoint Inhibitors and CAR T-Cell Therapy

Leveraging the immune system to treat cancer, however, also increases the potential for serious off-target effects.

The ASCO Post
Clinical Sequencing to Assess Tumor Mutational Burden as a Useful Biomarker to Immunotherapy in Various Solid Tumors

Tumor mutational burden has been considered as a useful marker to indicate patients who benefit from ICIs.

Therapeutic Advances in Medical Oncology
Standardization & Harmonization of Immuno-Oncology Toxicities

A report from the Association of Community Cancer Centers shows that IO treatment is increasingly being given to patients in community settings, not just in academic cancer centers.

Oncology Times - Latest Articles

mRNA in Cancer Immunotherapy: Beyond a Source of Antigen

Many novel immunotherapeutic strategies focus on the use of mRNA beyond its use as the source of tumor antigens. 

Molecular Cancer
Immune Regulation of the cGAS-STING Signaling Pathway in the Tumor Microenvironment and Its Clinical Application

STING agonists, as novel agonists, are used in preclinical research and in the treatment of various tumors via clinical trials and have displayed attractive application prospects.

OncoTargets and Therapy
The Impact of m6A RNA Modification in Therapy Resistance of Cancer: Implication in Chemotherapy, Radiotherapy, and Immunotherapy

This review focuses on m6A-associated regulation, mechanisms, and functions in acquired chemoresistance, radioresistance, and resistance to immunotherapy in cancer.

Frontiers in Oncology
Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies

Efforts to understand mechanisms of resistance and increase efficacy of immune checkpoint blockade in pancreatic cancer require the use of appropriate preclinical models in the laboratory.

A Small-Molecule P2RX7 Activator Promotes Anti-Tumor Immune Responses and Sensitizes Lung Tumor to Immunotherapy

Only a subpopulation of NSCLC patients responds to immunotherapies, highlighting the urgent need to develop therapeutic strategies to improve patient outcome.

Radiotherapy–Immunotherapy Combination: How Will We Bridge the Gap Between Pre-Clinical Promise and Effective Clinical Delivery?

This review assesses the important clinical questions that need to be addressed to successfully combine radiotherapy and immunotherapy treatments by rethinking approaches to...

Comprehensive Characterization of Immunological Profiles and Clinical Significance in Hepatocellular Carcinoma

Therapies targeting immune molecules have rapidly been adopted and advanced the treatment of hepatocellular carcinoma. 

Frontiers in Oncology
Immuno-oncology: Are TAM Receptors in Glioblastoma Friends or Foes?

In this study, investigators aim to cast a spotlight on the potential multidirectional effects of TAM receptors in glioblastoma and provide a better understanding for TAM receptor-related targeted

The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma

The aim of this review article is to characterize the profile of efficacy and safety of immuno-oncology-based monotherapies that failed to demonstrate significant benefit...

Targeting Hypoxia in the Tumor Microenvironment: A Potential Strategy to Improve Cancer Immunotherapy

In this review, the potential impact of hypoxia within the TME, in terms of key immune cell populations, and the contribution to immune suppression are discussed.

The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy

The role of the biochemical pathway of antigen presentation in cancer and how it can be modulated to enhance the efficacy of cancer immunotherapy is discussed.

PET Imaging Facilitates Antibody Screening for Synergistic Radioimmunotherapy With a 177Lu-Labeled αPD-L1 Antibody

The low response rate of immunotherapy, such as anti-PD-L1/PD-1 and anti-CTLA4, has limited its application to a wider population of cancer patients.

Immunocyte Membrane-Coated Nanoparticles for Cancer Immunotherapy

This review shows the latest research progress, the advantages, the disadvantages, and the application of immunocyte membrane-coated nanoparticles in cancer immunotherapy.

The Microbiome and Its Implications in Cancer Immunotherapy

This review mainly focuses on various microbes and their association with different types of cancer, responses to immunotherapeutic modulation...

The evolving landscape of predictive biomarkers in immuno‐oncology with a focus on spatial technologies

This review aims to provide an overview of the current methodologies that are used to profile the TME, which may provide insights into the immunopathology associated...

Society for Immunotherapy of Cancer Clinical Practice Guideline on Immunotherapy for the Treatment of Lymphoma

The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups.

Noninvasive Imaging of Cancer Immunotherapy

This study reviews recent developments in the field of noninvasive cancer imaging with a focus on immunotherapeutics and nuclear imaging technologies.

Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy

Exciting data from recent clinical trials have renewed interest in the field of cancer immunotherapy due to the potential of CAR NK cells in the production of “off-the-shelf” anti-cancer...

Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee

Immunotherapy is now a cornerstone for cancer treatment, and much attention has been placed on the identification of prognostic and predictive biomarker.

TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy.

Conventional dose finding designs in oncology drug development target on the identification of maximum tolerated (MTD), with assumption that MTD has...

Journal of Biopharmaceutical Statistics
Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy

Immuno-oncology and cell therapy, the frontier of cancer treatment, is a rapidly developing area that brings new opportunities to patients.

Contemporary Clinical Trials
Epigenetic Regulation of the Non-Coding Genome: Opportunities for Immuno-Oncology

The contribution of the non-coding genome to disease and its therapeutic potential have been largely unexplored. Recently, several epigenetic drugs developed for cancer treatment described...

Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.

The B cell surface antigen CD19 is a target for treating malignancies, such as precursor acute lymphoblastic leukemia and non-Hodgkin lymphoma.

Annals of Hematology
Immuno-oncology cell therapy branches out

Optimization of CAR-T cell technology and application other immune types such as NK cells are tackling the efficacy, cost logistical challenges therapies for cancer....

Biopharma Dealmakers
Multiomic analysis of cytokines in immuno-oncology.

Cytokines are a diverse group of peptides produced by different cell types including cancer cells and various subpopulations of immune system cells. 

Expert Review of Proteomics
Precision Tools in Immuno-Oncology: Synthetic Gene Circuits for Cancer Immunotherapy

Engineered mammalian cells for medical purposes are becoming a clinically relevant reality thanks to advances in synthetic biology that allow enhanced reliability and safety of cell-based therapies

Molecular Imaging in Immuno-Oncology: Current Status and Translational Perspectives.

Molecular imaging presents a prominent role for the management of oncological patients treated with ICIs.

Expert Review of Molecular Diagnostics
Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes.

In this article, current literature on the use of RWE for regulatory submissions is reviewed, with a focus on novel anticancer immunotherapies, and discussion on the utility and...

Future Oncology
A new era of immuno-oncology in acute myeloid leukemia - antibody-based therapies and immune checkpoint inhibition

This study aims to provide an overview of the recent advancements made in antibody-based approaches to the treatment of AML including monoclonal antibodies...

Best Practice &amp
Immuno-oncology for Hepatocellular Carcinoma: The Present and the Future.

Hepatocellular carcinoma is a highly prevalent and lethal cancer that many therapeutics are being tested for this disease.

Clinics in Liver Disease
Biotech and Breakthroughs in Immuno-Oncology.

The age of immuno-oncology has ushered in a rush within the biopharmaceutical industry.

Urologic Clinics of North America
Statistical and practical considerations in designing of immuno-oncology trials

The novel mechanism of action immunotherapy agents, in treatment various types cancer, poses unique challenges during the designing clinical trials. It is important to account for possi......

Journal of Biopharmaceutical Statistics
A concise review of bioanalytical methods of small molecule immuno-oncology drugs in cancer therapy.

Immuno-oncology (IO) is an emerging option to treat cancer malignancies.

Biomedical Chromatography
Physician treatment of metastatic triple-negative breast cancer in the immuno-oncology era: a discrete choice experiment.

To better understand the influence of treatment of triple-negative mBC, a discrete choice experiment was designed to examine the influence of patient age, disease severity...

Future Oncology
A perspective on HPK1 as a novel immuno-oncology drug target.

In this review, the role HPK1 in tumor immunity will be reviewed, with special emphasis on how T cells are negatively-regulated at different junctures of cancer-immunity...

Design for immuno-oncology clinical trials enrolling both responders and nonresponders.

A typical challenge facing the design and analysis of immuno-oncology trials is prevalence nonproportional hazards patterns manifested in Kaplan-Meier curves under time-to-event endpoints. 

Statistics in Medicine
Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology.

The discussion within this study will be centered around the genetic foundations governing tumor immunity and molecular determinants associated with clinical benefit from ICI therapy. 

Human Molecular Genetics
Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology

Immune checkpoint inhibitors (ICIs) are a novel treatment option for cancer therapy, which help direct the immune system to recognize and target cells.

Journal of the Formosan Medical Association
Personalized Immuno-oncology.

Cancer immunotherapy aims to control the immune system eradicate cancer cells and prevent their spread.

Medical Principles and Practice
Modeling Immune Checkpoint Inhibitor Efficacy in Syngeneic Mouse Tumors in an Ex Vivo Immuno-Oncology Dynamic Environment.

The immune checkpoint blockade represents a revolution in cancer therapy, with the potential to increase survival for many patients whom current treatments are not effective.

International Journal of Molecular Sciences
Epigenetic Regulation of the Non-Coding Genome: Opportunities for Immuno-Oncology

The contribution of the non-coding genome to disease and its therapeutic potential have been largely unexplored.


source list reference